BD SurePath is now officially validated for Bioperfectus HPV Real-Time PCR Kits!


Bioperfectus Human Papillomavirus Real Time PCR Kit & Human Papillomavirus Genotyping Real Time PCR Kit are free upgrading to meet different laboratories’ demands.

As latest guidelines released by countries and regions, we can tell that:

1)      HPV screening is now encouraged and considered for primary cervical cancer screening in more countries.

2)      The routine screening age usually falls between 30-65 years old.

3)      The frequency of HPV tests for routine screening is usually encouraged every 5 years.

4)      A retest is usually required after the positive result or intervention is followed up, contributing to the total potential test volume.






Screening age

HPV as primary screening and retest


2021 Jul

Guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition


30 – 65 yrs old

a regular screening interval of every 5 to 10 yrs when using HPV DNA detection as the primary screening test

•         Using HPV DNA primary screening test either with triage or without triage

•         Retest at 24 months: primary HPV (+) and triage (-)

•         Retest at 12 months: treated for histologically confirmed CIN2/3 or AIS or as a result of a positive screening test


2021 Apr

Updated Cervical Cancer Screening Guidelines


•         <21 yrs old, no screening

•         21-29 yrs old, cytology alone every 3 yrs

•         30-65 yrs old

- Cytology alone every 3 yrs

- hrHPV test alone (FDA approved) every 5 yrs

- Co-testing (hrHPV + cytology) every 5 yrs

•         >65 yrs old, stop after screening result (-)

•         hrHPV testing alone (FDA approved) every 5 yrs

•         Co-testing (hrHPV + cytology) every 5 yrs


2015 Aug

European guidelines for quality assurance

in cervical cancer screening

Second edition - Supplements


•         <30 yrs old, no screening

•         >35 yrs old, HPV screening every 5-10 yrs

•         >60 or 65 yrs old, stop after screening result (-)

•         hrHPV primary screening every 5 to 10 yrs

Saudi Arab

2016 Sep

Clinical practice

guidelines on the screening and treatment of precancerous lesions for cervical cancer prevention in Saudi Arabia


•         Within 3 yrs after marriage - 65 yrs old, HPV testing and/or cytology for universal screening

•         HPV DNA test followed by colposcopy or cytology (Pap test) followed by colposcopy to screen for CIN2+

•         HPV testing and/or cytology for universal screening


2018 June

Guidelines for

HPV‑DNA testing for cervical cancer screening in Brazil


•         <30 yrs old, no screening

•         30-65 yrs old, HPV testing or cytology every 5 yrs

•         >65 yrs old, stop after screening result (-)

•         HPV-DNA test can be the primary screening every 5 years

•         >30 yrs old with ASC-US can perform HPV-DNA test after 6 months



Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI)


•         <25 yrs old, no screening

•         25-29 yrs old, cytology alone every 3 yrs

•         30-65 yrs old, HPV testing or co-testing every 5 yrs

•         >65 yrs old, stop after screening result (-) and

no history of CIN2+ within the last 20 years

•        Primary HPV testing

•        Co-testing (HPV and cytology)

*In an Indian study, even a single round of HPV testing was shown to reduce the incidence of cervical cancer significantly

Latest Guidelines for Cervical Cancer Screening (general population without HIV/ADIS)

Source: Bioperfectus international marketing team database



ACOG: American College of Obstetricians and Gynecologists

ASCCP: American Society for Colposcopy and Cervical Pathology

SGO: Society of Gynecologic Oncology

USPSTF: the U.S. Preventive Services Task Force

ABPTGIC: The Brazilian Association for the Lower Genital Tract Pathology and Colposcopy

FOGSI: Federation of Obstetrics and Gynecologic Societies of India

Though all laboratories in each country and region shall develop their algorithms under local guidelines, which are recommended to follow a WHO strategy, a co-test combining the HPV DNA test and the cytologic test is usually put into practice as a screening strategy for cervical screening in clinical settings. As for cytologic tests, specimens preserved in a solution of Hologic ThinPrep® and BD SurePath™ are most commonly used for liquid-based cytologic tests.

Today Bioperfectus is pleased to announce that the Bioperfectus HPV DNA Test Total Solution is officially validated with a specimen collected by BD SurePath™ Collection Vial to better serve the work routine of laboratories in terms of cervical cancer screening.